{
    "root": "19b5c932-af2d-4a0b-ac4a-ba06c53c3219",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "lofexidine hydrochloride"
    },
    "value": "20241101",
    "ingredients": [
        {
            "name": "LOFEXIDINE HYDROCHLORIDE",
            "code": "V47G1SDI1B"
        },
        {
            "name": "CALCIUM STEARATE",
            "code": "776XM7047L"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 112",
            "code": "X7XJ6RM9Q2"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        }
    ],
    "indications": "lofexidine tablets indicated mitigation opioid withdrawal symptoms facilitate abrupt opioid discontinuation adults .",
    "contraindications": "usual lofexidine tablet three 0.18 mg tablets taken orally 4 times daily 5- 6-hour intervals . lofexidine tablet treatment may continued 14 days dosing guided symptoms . ( 2.1 ) discontinue lofexidine tablets gradual dose reduction 2 4 days . ( 2.1 ) hepatic renal impairment : adjustments recommended based degree impairment . ( 2.2 , 2.3 )",
    "warningsAndPrecautions": "supplied available 0.18 mg peach colored , round shaped biconvex film-coated tablets debossed `` l `` one side `` 1 `` side ; approximately 7 mm diameter . bottle 36 tablets……………………ndc 72205-246-42 bottle 96 tablets……………………ndc 72205-246-43 storage store original container controlled room temperature , 25°c ( 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . keep lofexidine tablets away excess heat moisture pharmacy dispensing . remove desiccant packs bottles tablets used . keep lofexidine tablets medicines reach children .",
    "adverseReactions": "none .",
    "indications_original": "Lofexidine tablets are indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.",
    "contraindications_original": "The usual lofexidine tablet dosage is three 0.18 mg tablets taken orally 4 times daily at 5- to 6-hour intervals. Lofexidine tablet  treatment may be continued for up to 14 days with dosing guided by symptoms. ( 2.1 ) Discontinue lofexidine tablets with a gradual dose reduction over 2 to 4 days. ( 2.1 ) Hepatic or Renal Impairment: Dosage adjustments are recommended based on degree of impairment. ( 2.2 , 2.3 )",
    "warningsAndPrecautions_original": "How Supplied\n                      Available as 0.18 mg peach colored, round shaped biconvex film-coated tablets debossed with ''L\" on one side and \"1\" on other side; approximately 7 mm in diameter. Bottle of 36 tablets……………………NDC 72205-246-42 Bottle of 96 tablets……………………NDC 72205-246-43 \n                     Storage\n                      Store in original container at controlled room temperature, 25°C (77°F); with excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Keep lofexidine tablets away from excess heat and moisture both in the pharmacy and after dispensing. Do not remove desiccant packs from bottles until all tablets are used. Keep lofexidine tablets and all medicines out of the reach of children.",
    "adverseReactions_original": "None."
}